IDEAYA Biosciences, Inc. (IDYA) stock
IDYANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 9/309% above fair value
$31.83+0.34 (+1.08%)
Close on Nov 13, 2026Market cap $3.07BP/E –Yield –
IDEAYA Biosciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
IDEAYA Biosciences's ebitda for the twelve months ending Jun 30, 2026 was -$214.14M. For fiscal 2025 it was -$156.61M. The highest annual figure on record is -$14.05M in fiscal 2017.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$156.61M | – |
| FY2024 | Dec 31, 2024 | -$324.59M | – |
| FY2023 | Dec 31, 2023 | -$131.95M | – |
| FY2022 | Dec 31, 2022 | -$60.40M | – |
| FY2021 | Dec 31, 2021 | -$48.54M | – |
| FY2020 | Dec 31, 2020 | -$33.96M | – |
| FY2019 | Dec 31, 2019 | -$42.87M | – |
| FY2018 | Dec 31, 2018 | -$35.53M | – |
| FY2017 | Dec 31, 2017 | -$14.05M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$121.59M | – |
| Q1 FY2026 | Mar 31, 2026 | -$107.86M | – |
| Q4 FY2025 | Dec 31, 2025 | -$93.85M | – |
| Q3 FY2025 | Sep 30, 2025 | $109.15M | – |
| Q2 FY2025 | Jun 30, 2025 | -$88.11M | – |
| Q1 FY2025 | Mar 31, 2025 | -$83.79M | – |
| Q4 FY2024 | Dec 31, 2024 | -$143.57M | – |
| Q3 FY2024 | Sep 30, 2024 | -$66.29M | – |
| Q2 FY2024 | Jun 30, 2024 | -$64.33M | – |
| Q1 FY2024 | Mar 31, 2024 | -$50.40M | – |
| Q4 FY2023 | Dec 31, 2023 | -$41.29M | – |
| Q3 FY2023 | Sep 30, 2023 | -$32.93M | -2713.2% |
| Q2 FY2023 | Jun 30, 2023 | -$32.11M | – |
| Q1 FY2023 | Mar 31, 2023 | -$25.69M | – |
| Q4 FY2022 | Dec 31, 2022 | -$25.89M | – |
| Q3 FY2022 | Sep 30, 2022 | $1.26M | – |
| Q2 FY2022 | Jun 30, 2022 | -$22.00M | – |
| Q1 FY2022 | Mar 31, 2022 | -$13.76M | – |
| Q4 FY2021 | Dec 31, 2021 | -$17.92M | – |
| Q3 FY2021 | Sep 30, 2021 | -$11.21M | – |
| Q2 FY2021 | Jun 30, 2021 | -$10.65M | – |
| Q1 FY2021 | Mar 31, 2021 | -$8.75M | – |
| Q4 FY2020 | Dec 31, 2020 | -$4.92M | – |
| Q3 FY2020 | Sep 30, 2020 | -$4.70M | – |
| Q2 FY2020 | Jun 30, 2020 | -$12.19M | – |
| Q1 FY2020 | Mar 31, 2020 | -$12.14M | – |
| Q4 FY2019 | Dec 31, 2019 | -$10.83M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.32M | – |
| Q2 FY2019 | Jun 30, 2019 | -$10.94M | – |
| Q1 FY2019 | Mar 31, 2019 | -$9.80M | – |
| Q4 FY2018 | Dec 31, 2018 | -$8.87M | – |
| Q3 FY2018 | Sep 30, 2018 | -$13.43M | – |
| Q2 FY2018 | Jun 30, 2018 | -$7.37M | – |
See a number that looks wrong?